{"ok":true,"total_studies":150,"studies":[{"nct_id":"NCT09696616","brief_title":"Phase 2 Trial of Genti619-tinib for the Treatment of Sickle Cell Disease","phase":"Phase 2","status":"Suspended","conditions":["Sickle Cell Disease"],"interventions":[{"type":"Combination Product","name":"Genti619-tinib"},{"type":"Drug","name":"Standard of Care"}],"sponsor":"Sanofi","principal_investigator":{"name":"M.C. Garassino","affiliation":"Baylor University Medical Center"},"locations":[{"facility":"Baylor University Medical Center","city":"Dallas","state":"TX","country":"United States"},{"facility":"Tufts Medical Center","city":"Boston","state":"MA","country":"United States"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"},{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"}],"start_date":"2026-07","enrollment":82},{"nct_id":"NCT04918995","brief_title":"CHECK-HL-712: A Phase 1 Study of Iso490-cel in Hodgkin Lymphoma","phase":"Phase 1","status":"Recruiting","conditions":["Hodgkin Lymphoma"],"interventions":[{"type":"Drug","name":"Iso490-cel"}],"sponsor":"Gilead Sciences","principal_investigator":{"name":"R. Herbst","affiliation":"NYU Langone Health"},"locations":[{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"},{"facility":"University of Colorado Hospital","city":"Aurora","state":"CO","country":"United States"},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"},{"facility":"University of Michigan","city":"Ann Arbor","state":"MI","country":"United States"}],"start_date":"2024-03","completion_date":"2031-03","enrollment":39},{"nct_id":"NCT07251860","brief_title":"A Study to Evaluate Juva696-cel in Patients With Non-Hodgkin Lymphoma (CARTITUDE-385)","phase":"Phase 2/Phase 3","status":"Recruiting","conditions":["Non-Hodgkin Lymphoma"],"interventions":[{"type":"Biological","name":"Juva696-cel"}],"sponsor":"AstraZeneca","principal_investigator":{"name":"L. Paz-Ares","affiliation":"University of Minnesota Medical Center"},"locations":[{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"}],"start_date":"2023-02","completion_date":"2027-04","enrollment":276},{"nct_id":"NCT08474238","brief_title":"Heli778-mab Plus Standard of Care in Acute Myeloid Leukemia","phase":"Phase 3","status":"Active, not recruiting","conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"Drug","name":"Heli778-mab"},{"type":"Drug","name":"Pembrolizumab"}],"sponsor":"Daiichi Sankyo","principal_investigator":{"name":"E. Winer","affiliation":"Massachusetts General Hospital"},"locations":[{"facility":"Massachusetts General Hospital","city":"Boston","state":"MA","country":"United States"},{"facility":"UT Southwestern Medical Center","city":"Dallas","state":"TX","country":"United States"},{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"MN","country":"United States"},{"facility":"University of North Carolina Lineberger","city":"Chapel Hill","state":"NC","country":"United States"}],"start_date":"2025-03","completion_date":"2028-05","enrollment":1306},{"nct_id":"NCT04807104","brief_title":"A Study to Evaluate Cara152-tide in Patients With Acute Lymphoblastic Leukemia (STUDY-651)","phase":"Phase 3","status":"Recruiting","conditions":["Acute Lymphoblastic Leukemia"],"interventions":[{"type":"Drug","name":"Cara152-tide"}],"sponsor":"Merck Sharp & Dohme","principal_investigator":{"name":"S. Tolaney","affiliation":"Dana-Farber Cancer Institute"},"locations":[{"facility":"Dana-Farber Cancer Institute","city":"Boston","state":"MA","country":"United States"}],"start_date":"2022-07","completion_date":"2031-09","enrollment":1058},{"nct_id":"NCT06029482","brief_title":"A Study to Evaluate Datopotamab Deruxtecan in Patients With Lung Neoplasms (DESTINY-Lung-348)","phase":"Phase 2","status":"Withdrawn","conditions":["Lung Neoplasms","Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"Drug","name":"Datopotamab Deruxtecan"}],"sponsor":"Merck Sharp & Dohme","principal_investigator":{"name":"N. Rizvi","affiliation":"Cleveland Clinic"},"locations":[{"facility":"Cleveland Clinic","city":"Cleveland","state":"OH","country":"United States"},{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"PA","country":"United States"},{"facility":"Massachusetts General Hospital","city":"Boston","state":"MA","country":"United States"},{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"}],"start_date":"2024-11","enrollment":69},{"nct_id":"NCT08362347","brief_title":"Iso551-cel Plus Standard of Care in Triple Negative Breast Neoplasms","phase":"Phase 2","status":"Withdrawn","conditions":["Triple Negative Breast Neoplasms"],"interventions":[{"type":"Drug","name":"Iso551-cel"}],"sponsor":"Gilead Sciences","principal_investigator":{"name":"S. Peters","affiliation":"Washington University in St. Louis"},"locations":[{"facility":"Washington University in St. Louis","city":"St. Louis","state":"MO","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"},{"facility":"Roswell Park Comprehensive Cancer Center","city":"Buffalo","state":"NY","country":"United States"},{"facility":"UT Southwestern Medical Center","city":"Dallas","state":"TX","country":"United States"}],"start_date":"2022-12","enrollment":111},{"nct_id":"NCT09584725","brief_title":"Beli831-tinib Plus Standard of Care in Multiple Myeloma","phase":"Phase 3","status":"Active, not recruiting","conditions":["Multiple Myeloma"],"interventions":[{"type":"Biological","name":"Beli831-tinib"}],"sponsor":"Sanofi","principal_investigator":{"name":"F. Andre","affiliation":"Princess Margaret Cancer Centre"},"locations":[{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"ON","country":"Canada"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"},{"facility":"UT Southwestern Medical Center","city":"Dallas","state":"TX","country":"United States"},{"facility":"Yale New Haven Hospital","city":"New Haven","state":"CT","country":"United States"},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"TX","country":"United States"}],"start_date":"2023-02","completion_date":"2029-12","enrollment":758},{"nct_id":"NCT05917591","brief_title":"DESTINY-Lung-480: A Phase 2 Study of Zenvara in Lung Neoplasms","phase":"Phase 2","status":"Completed","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"Biological","name":"Zenvara"},{"type":"Drug","name":"Cyclophosphamide"}],"sponsor":"Sanofi","principal_investigator":{"name":"A. Spira","affiliation":"Northwestern Memorial Hospital"},"locations":[{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"},{"facility":"Vanderbilt-Ingram Cancer Center","city":"Nashville","state":"TN","country":"United States"}],"start_date":"2022-01","completion_date":"2026-10","enrollment":141},{"nct_id":"NCT07139969","brief_title":"Phase 3 Trial of Ada396-cel for the Treatment of Acute Lymphoblastic Leukemia","phase":"Phase 3","status":"Active, not recruiting","conditions":["Acute Lymphoblastic Leukemia"],"interventions":[{"type":"Procedure","name":"Ada396-cel"},{"type":"Drug","name":"Cyclophosphamide"}],"sponsor":"Bristol-Myers Squibb","principal_investigator":{"name":"J. Brahmer","affiliation":"Emory Winship Cancer Institute"},"locations":[{"facility":"Emory Winship Cancer Institute","city":"Atlanta","state":"GA","country":"United States"},{"facility":"Tufts Medical Center","city":"Boston","state":"MA","country":"United States"},{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"}],"start_date":"2022-07","completion_date":"2028-03","enrollment":1388},{"nct_id":"NCT04561920","brief_title":"Phase 2/Phase 3 Trial of Omidubicel-onlv for the Treatment of Aplastic Anemia, Refractory","phase":"Phase 2/Phase 3","status":"Recruiting","conditions":["Severe Aplastic Anemia"],"interventions":[{"type":"Drug","name":"Omidubicel-onlv"}],"sponsor":"Bristol-Myers Squibb","principal_investigator":{"name":"S. Antonia","affiliation":"University of Minnesota Medical Center"},"locations":[{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"},{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"MN","country":"United States"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"}],"start_date":"2026-04","completion_date":"2027-01","enrollment":382},{"nct_id":"NCT09339541","brief_title":"Phase 3 Trial of Foli941-cel for the Treatment of Carcinoma, Renal Cell","phase":"Phase 3","status":"Completed","conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"Biological","name":"Foli941-cel"}],"sponsor":"National Cancer Institute (NCI)","principal_investigator":{"name":"R. Herbst","affiliation":"Northwestern Memorial Hospital"},"locations":[{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"},{"facility":"University of Colorado Hospital","city":"Aurora","state":"CO","country":"United States"},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"NY","country":"United States"}],"start_date":"2026-03","completion_date":"2026-08","enrollment":1228},{"nct_id":"NCT08117163","brief_title":"Iso664-mab Plus Standard of Care in Hodgkin Lymphoma","phase":"Phase 2","status":"Suspended","conditions":["Hodgkin Lymphoma"],"interventions":[{"type":"Procedure","name":"Iso664-mab"}],"sponsor":"Aurelia Therapeutics","principal_investigator":{"name":"F. Andre","affiliation":"Roswell Park Comprehensive Cancer Center"},"locations":[{"facility":"Roswell Park Comprehensive Cancer Center","city":"Buffalo","state":"NY","country":"United States"},{"facility":"Vanderbilt-Ingram Cancer Center","city":"Nashville","state":"TN","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"}],"start_date":"2025-01","enrollment":94},{"nct_id":"NCT06894785","brief_title":"A Study to Evaluate Donumicel-vrnz in Patients With Aplastic Anemia, Refractory (AUGMENT-726)","phase":"Phase 2","status":"Recruiting","conditions":["Severe Aplastic Anemia","Aplastic Anemia, Refractory"],"interventions":[{"type":"Biological","name":"Donumicel-vrnz"}],"sponsor":"Bluebird Bio","principal_investigator":{"name":"H. Borghaei","affiliation":"UCLA Health"},"locations":[{"facility":"UCLA Health","city":"Los Angeles","state":"CA","country":"United States"},{"facility":"Roswell Park Comprehensive Cancer Center","city":"Buffalo","state":"NY","country":"United States"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"},{"facility":"Cleveland Clinic","city":"Cleveland","state":"OH","country":"United States"},{"facility":"Baylor University Medical Center","city":"Dallas","state":"TX","country":"United States"}],"start_date":"2026-05","completion_date":"2030-03","enrollment":128},{"nct_id":"NCT05672407","brief_title":"Ada604-mab Plus Standard of Care in Sickle Cell Disease","phase":"Phase 2","status":"Completed","conditions":["Sickle Cell Disease"],"interventions":[{"type":"Drug","name":"Ada604-mab"}],"sponsor":"Bristol-Myers Squibb","principal_investigator":{"name":"S. Tolaney","affiliation":"Cleveland Clinic"},"locations":[{"facility":"Cleveland Clinic","city":"Cleveland","state":"OH","country":"United States"}],"start_date":"2023-07","completion_date":"2026-02","enrollment":177},{"nct_id":"NCT04450029","brief_title":"Beli218-vec Plus Standard of Care in Diffuse Large B-Cell Lymphoma","phase":"Phase 3","status":"Completed","conditions":["Non-Hodgkin Lymphoma","Diffuse Large B-Cell Lymphoma"],"interventions":[{"type":"Drug","name":"Beli218-vec"}],"sponsor":"Bristol-Myers Squibb","principal_investigator":{"name":"J. Brahmer","affiliation":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center"},"locations":[{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"},{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"PA","country":"United States"},{"facility":"UCLA Health","city":"Los Angeles","state":"CA","country":"United States"},{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"}],"start_date":"2026-02","completion_date":"2026-01","enrollment":276},{"nct_id":"NCT09227650","brief_title":"A Study to Evaluate Cord Blood-Derived Cell Therapy in Patients With Aplastic Anemia, Refractory (EXPAND-337)","phase":"Phase 2","status":"Recruiting","conditions":["Severe Aplastic Anemia","Aplastic Anemia, Refractory"],"interventions":[{"type":"Biological","name":"Cord Blood-Derived Cell Therapy"},{"type":"Drug","name":"Fludarabine"}],"sponsor":"Daiichi Sankyo","principal_investigator":{"name":"M. Reck","affiliation":"Ohio State University Wexner Medical Center"},"locations":[{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"}],"start_date":"2022-10","completion_date":"2030-09","enrollment":83},{"nct_id":"NCT08005272","brief_title":"MajesTEC-217: A Phase 2 Study of Juva661-tide in Multiple Myeloma","phase":"Phase 2","status":"Recruiting","conditions":["Multiple Myeloma"],"interventions":[{"type":"Biological","name":"Juva661-tide"}],"sponsor":"Aurelia Therapeutics","principal_investigator":{"name":"E. Winer","affiliation":"NYU Langone Health"},"locations":[{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"},{"facility":"University of North Carolina Lineberger","city":"Chapel Hill","state":"NC","country":"United States"},{"facility":"Vanderbilt-Ingram Cancer Center","city":"Nashville","state":"TN","country":"United States"}],"start_date":"2026-09","completion_date":"2027-07","enrollment":197},{"nct_id":"NCT06782894","brief_title":"Phase 2 Trial of Deli529-tide for the Treatment of Hodgkin Lymphoma","phase":"Phase 2","status":"Completed","conditions":["Hodgkin Lymphoma"],"interventions":[{"type":"Drug","name":"Deli529-tide"},{"type":"Drug","name":"Cyclophosphamide"}],"sponsor":"Janssen Research & Development, LLC","principal_investigator":{"name":"J. Cortes","affiliation":"University of North Carolina Lineberger"},"locations":[{"facility":"University of North Carolina Lineberger","city":"Chapel Hill","state":"NC","country":"United States"},{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"TX","country":"United States"}],"start_date":"2026-07","completion_date":"2026-12","enrollment":134},{"nct_id":"NCT05560516","brief_title":"CLIMB-764: A Phase 2 Study of Juva202-tide in Sickle Cell Disease","phase":"Phase 2","status":"Recruiting","conditions":["Sickle Cell Disease"],"interventions":[{"type":"Drug","name":"Juva202-tide"}],"sponsor":"Bristol-Myers Squibb","principal_investigator":{"name":"J. Brahmer","affiliation":"Mount Sinai Health System"},"locations":[{"facility":"Mount Sinai Health System","city":"New York","state":"NY","country":"United States"},{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"ON","country":"Canada"}],"start_date":"2026-01","completion_date":"2027-05","enrollment":68},{"nct_id":"NCT07000397","brief_title":"Cyclophosphamide + Fludarabine Plus Standard of Care in Hematopoietic Stem Cell Transplantation","phase":"Phase 2","status":"Completed","conditions":["Hematopoietic Stem Cell Transplantation","Cord Blood Transplantation"],"interventions":[{"type":"Drug","name":"Cyclophosphamide + Fludarabine"}],"sponsor":"Pfizer","principal_investigator":{"name":"H. Borghaei","affiliation":"Princess Margaret Cancer Centre"},"locations":[{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"ON","country":"Canada"},{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"},{"facility":"City of Hope","city":"Duarte","state":"CA","country":"United States"}],"start_date":"2025-06","completion_date":"2026-03","enrollment":148},{"nct_id":"NCT08222775","brief_title":"A Study to Evaluate Juva183-cel in Patients With Diffuse Large B-Cell Lymphoma (ELARA-310)","phase":"Phase 1","status":"Active, not recruiting","conditions":["Diffuse Large B-Cell Lymphoma","Non-Hodgkin Lymphoma"],"interventions":[{"type":"Drug","name":"Juva183-cel"},{"type":"Drug","name":"Standard of Care"}],"sponsor":"Aurelia Therapeutics","principal_investigator":{"name":"A. Spira","affiliation":"Duke University Medical Center"},"locations":[{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"},{"facility":"University of Wisconsin Carbone Cancer Center","city":"Madison","state":"WI","country":"United States"}],"start_date":"2023-10","completion_date":"2028-02","enrollment":27},{"nct_id":"NCT04555641","brief_title":"Phase 1 Trial of Ada920-mab for the Treatment of Sickle Cell Disease","phase":"Phase 1","status":"Suspended","conditions":["Sickle Cell Disease"],"interventions":[{"type":"Procedure","name":"Ada920-mab"}],"sponsor":"Pfizer","principal_investigator":{"name":"T. Mok","affiliation":"Northwestern Memorial Hospital"},"locations":[{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"},{"facility":"University of Wisconsin Carbone Cancer Center","city":"Madison","state":"WI","country":"United States"},{"facility":"Emory Winship Cancer Institute","city":"Atlanta","state":"GA","country":"United States"},{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"PA","country":"United States"}],"start_date":"2023-04","enrollment":40},{"nct_id":"NCT05778019","brief_title":"A Study to Evaluate Cyclophosphamide + Fludarabine in Patients With Cord Blood Transplantation (ENGRAFT-219)","phase":"N/A","status":"Recruiting","conditions":["Cord Blood Transplantation","Hematopoietic Stem Cell Transplantation"],"interventions":[{"type":"Device","name":"Cyclophosphamide + Fludarabine"},{"type":"Drug","name":"Standard of Care"}],"sponsor":"Bluebird Bio","principal_investigator":{"name":"H. Rugo","affiliation":"Massachusetts General Hospital"},"locations":[{"facility":"Massachusetts General Hospital","city":"Boston","state":"MA","country":"United States"},{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"}],"start_date":"2022-02","completion_date":"2027-04","enrollment":289},{"nct_id":"NCT08110884","brief_title":"A Study to Evaluate Genti967-mab in Patients With Acute Myeloid Leukemia (CARTITUDE-379)","phase":"N/A","status":"Recruiting","conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"Biological","name":"Genti967-mab"}],"sponsor":"Pfizer","principal_investigator":{"name":"A. Spira","affiliation":"Indiana University Simon Cancer Center"},"locations":[{"facility":"Indiana University Simon Cancer Center","city":"Indianapolis","state":"IN","country":"United States"},{"facility":"Stanford Health Care","city":"Stanford","state":"CA","country":"United States"},{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"},{"facility":"Baylor University Medical Center","city":"Dallas","state":"TX","country":"United States"},{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"}],"start_date":"2022-05","completion_date":"2031-02","enrollment":196},{"nct_id":"NCT09333262","brief_title":"A Study to Evaluate Cord Blood-Derived Cell Therapy in Patients With Aplastic Anemia, Refractory (CONFIRM-353)","phase":"Phase 2","status":"Withdrawn","conditions":["Aplastic Anemia, Refractory","Severe Aplastic Anemia"],"interventions":[{"type":"Drug","name":"Cord Blood-Derived Cell Therapy"}],"sponsor":"Sanofi","principal_investigator":{"name":"M. Krop","affiliation":"Yale New Haven Hospital"},"locations":[{"facility":"Yale New Haven Hospital","city":"New Haven","state":"CT","country":"United States"},{"facility":"Dana-Farber Cancer Institute","city":"Boston","state":"MA","country":"United States"}],"start_date":"2022-06","enrollment":150},{"nct_id":"NCT05666128","brief_title":"Heli925-tinib Plus Standard of Care in Triple Negative Breast Neoplasms","phase":"Phase 2","status":"Completed","conditions":["Triple Negative Breast Neoplasms"],"interventions":[{"type":"Device","name":"Heli925-tinib"},{"type":"Drug","name":"Carboplatin"}],"sponsor":"Gilead Sciences","principal_investigator":{"name":"A. Spira","affiliation":"Princess Margaret Cancer Centre"},"locations":[{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"ON","country":"Canada"},{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"},{"facility":"University of Colorado Hospital","city":"Aurora","state":"CO","country":"United States"}],"start_date":"2025-03","completion_date":"2025-03","enrollment":152},{"nct_id":"NCT06888506","brief_title":"A Study to Evaluate Eve649-tinib in Patients With Triple Negative Breast Neoplasms (OlympiAD-407)","phase":"Phase 1","status":"Active, not recruiting","conditions":["Triple Negative Breast Neoplasms"],"interventions":[{"type":"Drug","name":"Eve649-tinib"},{"type":"Drug","name":"Fludarabine"}],"sponsor":"Helika Therapeutics","principal_investigator":{"name":"C. Robert","affiliation":"Fred Hutchinson Cancer Center"},"locations":[{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"},{"facility":"Massachusetts General Hospital","city":"Boston","state":"MA","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"},{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"},{"facility":"UT Southwestern Medical Center","city":"Dallas","state":"TX","country":"United States"}],"start_date":"2025-09","completion_date":"2030-03","enrollment":23},{"nct_id":"NCT04779423","brief_title":"MAIA-617: A Phase 2 Study of Iso721-tinib in Multiple Myeloma","phase":"Phase 2","status":"Active, not recruiting","conditions":["Multiple Myeloma"],"interventions":[{"type":"Drug","name":"Iso721-tinib"},{"type":"Drug","name":"Fludarabine"}],"sponsor":"Daiichi Sankyo","principal_investigator":{"name":"R. Herbst","affiliation":"University of Pittsburgh Medical Center"},"locations":[{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"PA","country":"United States"},{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"},{"facility":"UCSF Helen Diller Family Comprehensive Cancer Center","city":"San Francisco","state":"CA","country":"United States"}],"start_date":"2025-12","completion_date":"2030-03","enrollment":110},{"nct_id":"NCT06001801","brief_title":"A Study to Evaluate Juva812-cel in Patients With Sickle Cell Disease (REVEAL-731)","phase":"Phase 1","status":"Completed","conditions":["Sickle Cell Disease"],"interventions":[{"type":"Biological","name":"Juva812-cel"},{"type":"Drug","name":"Standard of Care"}],"sponsor":"Bristol-Myers Squibb","principal_investigator":{"name":"S. Modi","affiliation":"Duke University Medical Center"},"locations":[{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"},{"facility":"University of North Carolina Lineberger","city":"Chapel Hill","state":"NC","country":"United States"}],"start_date":"2025-08","completion_date":"2025-06","enrollment":11},{"nct_id":"NCT08187571","brief_title":"N/A Trial of Beli552-vec for the Treatment of Hodgkin Lymphoma","phase":"N/A","status":"Recruiting","conditions":["Hodgkin Lymphoma"],"interventions":[{"type":"Biological","name":"Beli552-vec"}],"sponsor":"Pfizer","principal_investigator":{"name":"F. Andre","affiliation":"NYU Langone Health"},"locations":[{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"}],"start_date":"2024-07","completion_date":"2029-09","enrollment":145},{"nct_id":"NCT06965193","brief_title":"Phase 2 Trial of Juva426-cel for the Treatment of Triple Negative Breast Neoplasms","phase":"Phase 2","status":"Suspended","conditions":["Triple Negative Breast Neoplasms"],"interventions":[{"type":"Drug","name":"Juva426-cel"}],"sponsor":"Sanofi","principal_investigator":{"name":"C. Saura","affiliation":"Duke University Medical Center"},"locations":[{"facility":"Duke University Medical Center","city":"Durham","state":"NC","country":"United States"},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"}],"start_date":"2025-08","enrollment":142},{"nct_id":"NCT04632328","brief_title":"Phase 3 Trial of Datopotamab Deruxtecan for the Treatment of Carcinoma, Non-Small-Cell Lung","phase":"Phase 3","status":"Recruiting","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"Biological","name":"Datopotamab Deruxtecan"}],"sponsor":"Bluebird Bio","principal_investigator":{"name":"C. Saura","affiliation":"University of Minnesota Medical Center"},"locations":[{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"}],"start_date":"2023-07","completion_date":"2031-04","enrollment":1151},{"nct_id":"NCT09409949","brief_title":"Donumicel-vrnz Plus Standard of Care in Cord Blood Transplantation","phase":"Phase 2","status":"Completed","conditions":["Cord Blood Transplantation","Hematopoietic Stem Cell Transplantation"],"interventions":[{"type":"Procedure","name":"Donumicel-vrnz"},{"type":"Drug","name":"Cyclophosphamide"}],"sponsor":"Aurelia Therapeutics","principal_investigator":{"name":"G. Curigliano","affiliation":"Stanford Health Care"},"locations":[{"facility":"Stanford Health Care","city":"Stanford","state":"CA","country":"United States"},{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"PA","country":"United States"}],"start_date":"2024-02","completion_date":"2025-03","enrollment":190},{"nct_id":"NCT07077084","brief_title":"Foli978-vec Plus Standard of Care in Sickle Cell Disease","phase":"Phase 2","status":"Enrolling by invitation","conditions":["Sickle Cell Disease"],"interventions":[{"type":"Drug","name":"Foli978-vec"},{"type":"Drug","name":"Cyclophosphamide"}],"sponsor":"Novartis Pharmaceuticals","principal_investigator":{"name":"H. Borghaei","affiliation":"Emory Winship Cancer Institute"},"locations":[{"facility":"Emory Winship Cancer Institute","city":"Atlanta","state":"GA","country":"United States"},{"facility":"UCSF Helen Diller Family Comprehensive Cancer Center","city":"San Francisco","state":"CA","country":"United States"},{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"ON","country":"Canada"},{"facility":"University of Colorado Hospital","city":"Aurora","state":"CO","country":"United States"}],"start_date":"2026-07","completion_date":"2029-06","enrollment":124},{"nct_id":"NCT05854706","brief_title":"Phase 1 Trial of Cara349-tide for the Treatment of Diffuse Large B-Cell Lymphoma","phase":"Phase 1","status":"Recruiting","conditions":["Diffuse Large B-Cell Lymphoma","Non-Hodgkin Lymphoma"],"interventions":[{"type":"Drug","name":"Cara349-tide"}],"sponsor":"Sanofi","principal_investigator":{"name":"E. Winer","affiliation":"City of Hope"},"locations":[{"facility":"City of Hope","city":"Duarte","state":"CA","country":"United States"},{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"MN","country":"United States"},{"facility":"Cleveland Clinic","city":"Cleveland","state":"OH","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"}],"start_date":"2022-10","completion_date":"2029-12","enrollment":24},{"nct_id":"NCT09521840","brief_title":"A Study to Evaluate Juva195-tide in Patients With Hodgkin Lymphoma (AETHERA-614)","phase":"Phase 2","status":"Completed","conditions":["Hodgkin Lymphoma"],"interventions":[{"type":"Drug","name":"Juva195-tide"}],"sponsor":"National Cancer Institute (NCI)","principal_investigator":{"name":"H. Rugo","affiliation":"Fred Hutchinson Cancer Center"},"locations":[{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"},{"facility":"City of Hope","city":"Duarte","state":"CA","country":"United States"}],"start_date":"2022-07","completion_date":"2025-05","enrollment":146},{"nct_id":"NCT08299462","brief_title":"AML-251: A Phase 3 Study of Cara678-tide in Acute Myeloid Leukemia","phase":"Phase 3","status":"Recruiting","conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"Combination Product","name":"Cara678-tide"},{"type":"Drug","name":"Standard of Care"}],"sponsor":"National Cancer Institute (NCI)","principal_investigator":{"name":"M. Reck","affiliation":"Yale New Haven Hospital"},"locations":[{"facility":"Yale New Haven Hospital","city":"New Haven","state":"CT","country":"United States"},{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"}],"start_date":"2023-10","completion_date":"2030-02","enrollment":1028},{"nct_id":"NCT04408546","brief_title":"A Study to Evaluate Ada390-tinib in Patients With Acute Lymphoblastic Leukemia (ALCANZA-607)","phase":"Phase 1","status":"Completed","conditions":["Acute Lymphoblastic Leukemia"],"interventions":[{"type":"Biological","name":"Ada390-tinib"}],"sponsor":"Merck Sharp & Dohme","principal_investigator":{"name":"A. Spira","affiliation":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center"},"locations":[{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"},{"facility":"Emory Winship Cancer Institute","city":"Atlanta","state":"GA","country":"United States"},{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"},{"facility":"Stanford Health Care","city":"Stanford","state":"CA","country":"United States"}],"start_date":"2025-12","completion_date":"2026-09","enrollment":12},{"nct_id":"NCT09186167","brief_title":"Phase 2 Trial of Nivolumab + Ipilimumab for the Treatment of Lung Neoplasms","phase":"Phase 2","status":"Recruiting","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"Drug","name":"Nivolumab + Ipilimumab"},{"type":"Drug","name":"Standard of Care"}],"sponsor":"National Cancer Institute (NCI)","principal_investigator":{"name":"H. Borghaei","affiliation":"Tufts Medical Center"},"locations":[{"facility":"Tufts Medical Center","city":"Boston","state":"MA","country":"United States"},{"facility":"Stanford Health Care","city":"Stanford","state":"CA","country":"United States"},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"},{"facility":"Emory Winship Cancer Institute","city":"Atlanta","state":"GA","country":"United States"},{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"}],"start_date":"2023-01","completion_date":"2028-01","enrollment":186},{"nct_id":"NCT05193627","brief_title":"Phase 3 Trial of Genti305-mab for the Treatment of Myelodysplastic Syndromes","phase":"Phase 3","status":"Active, not recruiting","conditions":["Myelodysplastic Syndromes"],"interventions":[{"type":"Drug","name":"Genti305-mab"},{"type":"Drug","name":"Carboplatin"}],"sponsor":"Merck Sharp & Dohme","principal_investigator":{"name":"H. Rugo","affiliation":"NYU Langone Health"},"locations":[{"facility":"NYU Langone Health","city":"New York","state":"NY","country":"United States"},{"facility":"Indiana University Simon Cancer Center","city":"Indianapolis","state":"IN","country":"United States"},{"facility":"University of Wisconsin Carbone Cancer Center","city":"Madison","state":"WI","country":"United States"}],"start_date":"2022-07","completion_date":"2028-01","enrollment":926},{"nct_id":"NCT06416005","brief_title":"A Study to Evaluate Deli675-tinib in Patients With Non-Hodgkin Lymphoma (POLARIX-755)","phase":"Phase 2","status":"Active, not recruiting","conditions":["Non-Hodgkin Lymphoma"],"interventions":[{"type":"Drug","name":"Deli675-tinib"}],"sponsor":"Novartis Pharmaceuticals","principal_investigator":{"name":"H. Borghaei","affiliation":"Mayo Clinic Rochester"},"locations":[{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"MN","country":"United States"}],"start_date":"2023-01","completion_date":"2027-12","enrollment":177},{"nct_id":"NCT07638383","brief_title":"Donumicel-vrnz Plus Standard of Care in Aplastic Anemia, Refractory","phase":"Phase 3","status":"Withdrawn","conditions":["Severe Aplastic Anemia","Aplastic Anemia, Refractory"],"interventions":[{"type":"Combination Product","name":"Donumicel-vrnz"}],"sponsor":"Aurelia Therapeutics","principal_investigator":{"name":"M. Reck","affiliation":"Yale New Haven Hospital"},"locations":[{"facility":"Yale New Haven Hospital","city":"New Haven","state":"CT","country":"United States"},{"facility":"UCSF Helen Diller Family Comprehensive Cancer Center","city":"San Francisco","state":"CA","country":"United States"},{"facility":"Massachusetts General Hospital","city":"Boston","state":"MA","country":"United States"}],"start_date":"2024-04","enrollment":1169},{"nct_id":"NCT08860761","brief_title":"Phase 3 Trial of Juva357-cel for the Treatment of Acute Myeloid Leukemia","phase":"Phase 3","status":"Completed","conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"Combination Product","name":"Juva357-cel"}],"sponsor":"AstraZeneca","principal_investigator":{"name":"H. Rugo","affiliation":"Yale New Haven Hospital"},"locations":[{"facility":"Yale New Haven Hospital","city":"New Haven","state":"CT","country":"United States"},{"facility":"Emory Winship Cancer Institute","city":"Atlanta","state":"GA","country":"United States"},{"facility":"Roswell Park Comprehensive Cancer Center","city":"Buffalo","state":"NY","country":"United States"},{"facility":"Fred Hutchinson Cancer Center","city":"Seattle","state":"WA","country":"United States"},{"facility":"Washington University in St. Louis","city":"St. Louis","state":"MO","country":"United States"}],"start_date":"2026-12","completion_date":"2026-12","enrollment":475},{"nct_id":"NCT04083140","brief_title":"Eve211-tinib Plus Standard of Care in Triple Negative Breast Neoplasms","phase":"Phase 2","status":"Recruiting","conditions":["Triple Negative Breast Neoplasms"],"interventions":[{"type":"Biological","name":"Eve211-tinib"}],"sponsor":"Hoffmann-La Roche","principal_investigator":{"name":"H. Borghaei","affiliation":"University of Minnesota Medical Center"},"locations":[{"facility":"University of Minnesota Medical Center","city":"Minneapolis","state":"MN","country":"United States"},{"facility":"UCSF Helen Diller Family Comprehensive Cancer Center","city":"San Francisco","state":"CA","country":"United States"},{"facility":"UCLA Health","city":"Los Angeles","state":"CA","country":"United States"},{"facility":"Washington University in St. Louis","city":"St. Louis","state":"MO","country":"United States"},{"facility":"Massachusetts General Hospital","city":"Boston","state":"MA","country":"United States"}],"start_date":"2026-02","completion_date":"2027-06","enrollment":81},{"nct_id":"NCT05305518","brief_title":"DESTINY-Lung-433: A Phase 4 Study of Datopotamab Deruxtecan in Carcinoma, Non-Small-Cell Lung","phase":"Phase 4","status":"Active, not recruiting","conditions":["Lung Neoplasms"],"interventions":[{"type":"Drug","name":"Datopotamab Deruxtecan"}],"sponsor":"Gilead Sciences","principal_investigator":{"name":"L. Paz-Ares","affiliation":"Stanford Health Care"},"locations":[{"facility":"Stanford Health Care","city":"Stanford","state":"CA","country":"United States"},{"facility":"Ohio State University Wexner Medical Center","city":"Columbus","state":"OH","country":"United States"},{"facility":"University of Wisconsin Carbone Cancer Center","city":"Madison","state":"WI","country":"United States"},{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"PA","country":"United States"}],"start_date":"2026-05","completion_date":"2028-03","enrollment":2448},{"nct_id":"NCT06527896","brief_title":"Ex Vivo Expanded Cord Blood Unit Plus Standard of Care in Hematopoietic Stem Cell Transplantation","phase":"Phase 4","status":"Active, not recruiting","conditions":["Cord Blood Transplantation"],"interventions":[{"type":"Drug","name":"Ex Vivo Expanded Cord Blood Unit"}],"sponsor":"Novartis Pharmaceuticals","principal_investigator":{"name":"C. Saura","affiliation":"UCLA Health"},"locations":[{"facility":"UCLA Health","city":"Los Angeles","state":"CA","country":"United States"},{"facility":"Roswell Park Comprehensive Cancer Center","city":"Buffalo","state":"NY","country":"United States"},{"facility":"City of Hope","city":"Duarte","state":"CA","country":"United States"},{"facility":"Tufts Medical Center","city":"Boston","state":"MA","country":"United States"}],"start_date":"2026-12","completion_date":"2029-07","enrollment":1191},{"nct_id":"NCT07750274","brief_title":"A Study to Evaluate Foli977-cel in Patients With Multiple Myeloma (CARTITUDE-392)","phase":"Phase 3","status":"Completed","conditions":["Multiple Myeloma"],"interventions":[{"type":"Drug","name":"Foli977-cel"}],"sponsor":"Hoffmann-La Roche","principal_investigator":{"name":"M. Krop","affiliation":"Princess Margaret Cancer Centre"},"locations":[{"facility":"Princess Margaret Cancer Centre","city":"Toronto","state":"ON","country":"Canada"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"}],"start_date":"2022-03","completion_date":"2026-09","enrollment":300},{"nct_id":"NCT08972652","brief_title":"Beli256-mab Plus Standard of Care in Acute Lymphoblastic Leukemia","phase":"Phase 1/Phase 2","status":"Active, not recruiting","conditions":["Acute Lymphoblastic Leukemia"],"interventions":[{"type":"Biological","name":"Beli256-mab"}],"sponsor":"Bluebird Bio","principal_investigator":{"name":"M.C. Garassino","affiliation":"Northwestern Memorial Hospital"},"locations":[{"facility":"Northwestern Memorial Hospital","city":"Chicago","state":"IL","country":"United States"},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"TX","country":"United States"},{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"PA","country":"United States"},{"facility":"Mayo Clinic Rochester","city":"Rochester","state":"MN","country":"United States"},{"facility":"Vanderbilt-Ingram Cancer Center","city":"Nashville","state":"TN","country":"United States"}],"start_date":"2024-11","completion_date":"2030-09","enrollment":75},{"nct_id":"NCT04195031","brief_title":"Cord Blood-Derived Cell Therapy Plus Standard of Care in Severe Aplastic Anemia","phase":"Phase 2/Phase 3","status":"Withdrawn","conditions":["Aplastic Anemia, Refractory"],"interventions":[{"type":"Biological","name":"Cord Blood-Derived Cell Therapy"}],"sponsor":"Aurelia Therapeutics","principal_investigator":{"name":"S. Antonia","affiliation":"Hospital of the University of Pennsylvania"},"locations":[{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"PA","country":"United States"},{"facility":"Stanford Health Care","city":"Stanford","state":"CA","country":"United States"},{"facility":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"MD","country":"United States"}],"start_date":"2023-04","enrollment":194}]}